Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy
- 15 December 2018
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 46 (6), 623-627
- https://doi.org/10.3899/jrheum.171495
Abstract
Objective A pathogenic role of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibodies has been proposed. Our objective was to assess efficacy of rituximab (RTX) in anti-HMGCR immune-mediated necrotizing myopathy. Methods All patients who had been treated with RTX were retrospectively reviewed to assess features and outcome. Results Three of 9 patients demonstrated stable or improved muscle strength ± decline in creatine kinase levels, or T2/short-tau inversion recovery hypersignal decrease on magnetic resonance imaging following RTX treatment. RTX permitted intravenous immunoglobulin discontinuation and corticosteroid reduction to low dose in 2 patients. Conclusion One-third of patients with refractory anti-HMGCR had improved strength or other evidence of improved disease activity following RTX treatment.Keywords
This publication has 14 references indexed in Scilit:
- Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspectiveNeuromuscular Disorders, 2016
- Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severityAnnals Of The Rheumatic Diseases, 2016
- Clinical course and treatment of anti-HMGCR antibody–associated necrotizing autoimmune myopathyNeurology Neuroimmunology & Neuroinflammation, 2015
- Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing MyopathiesMedicine, 2014
- Predictors of Clinical Improvement in Rituximab‐Treated Refractory Adult and Juvenile Dermatomyositis and Adult PolymyositisArthritis & Rheumatology, 2013
- Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo‐phase trialArthritis & Rheumatism, 2012
- Long-lived autoreactive plasma cells drive persistent autoimmune inflammationNature Reviews Rheumatology, 2011
- Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathyArthritis & Rheumatism, 2010
- A novel autoantibody recognizing 200‐kd and 100‐kd proteins is associated with an immune‐mediated necrotizing myopathyArthritis & Rheumatism, 2010
- CD20-Targeted Therapy: The Next Generation of AntibodiesSeminars in Hematology, 2010